Juliana Mercer, ma'aikaciyar Marine Corps Marine da ta yi aiki a Iraki da Afganistan, ta je neman namomin kaza a Costa Rica. Ta yi hulɗa da ƙungiyar sa-kai da ke taimaka wa tsoffin sojojin yaƙi da hanyoyin kwantar da hankali. A cewar Ma'aikatar Harkokin Tsohon Sojoji, daya cikin XNUMX mazan tsofaffi da kusan biyu a cikin XNUMX mata tsofaffi suna fama da PTSD.
Mercer wanda ya yi aiki a jimlar shekaru 16, yanzu daraktan bayar da shawarwari na tsoffin soji na Kungiyar Tallafawa Tsofaffi. Cigaban Waraka, yana ba da shawarar yin amfani da MDMA da sauran hanyoyin kwantar da hankali don taimakawa tsofaffin da ke fama da matsalolin kiwon lafiya da yawa.
Psychedelics: Entheogens da enactogens
Tsohuwar Marine masu ba da shawarar haɗa tsoffin sojoji zuwa waɗannan hanyoyin kwantar da hankali. Kodayake MDMA an fi saninta da ecstasy ko molly, akwai manyan bambance-bambancen sinadarai tsakanin masu tunanin titi da bambance-bambancen da ake amfani da su wajen jiyya.
Psychedelics ana daukar su entheogens, wanda idan aka cinye su ke haifar da canjin fahimtar gaskiya. Tasirin hallucinatory. Wannan shine maganin sinadari na gargajiya da masu amfani da su ke amfani da shi azaman maganin jam'iyya.
A gefe guda, hanyoyin kwantar da hankali na MDMA waɗanda ƙungiyoyi kamar Healing Breakthrough ke bi su ne entactogens. Waɗannan nau'ikan kaddarorin sinadarai suna haifar da "ƙasassun yanayi na zurfafa tunani da tunani" da "halayyar zamantakewa," a cewar wata kasida a cikin Frontiers of Psychiatry ta likitan chemist David Nichols.
Masu bincike sun riga sun sami kyakkyawan sakamako na farko. A cikin 2017, Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) ta sanya MDMA a matsayin "maganin nasara" don magance matsalar damuwa bayan tashin hankali. Psilocybin don maganin damuwa da damuwa sun sami wannan nadi a cikin 2019.
Ƙungiyar Multidisciplinary for Psychedelic Studies, ko MAPS a takaice, tana binciken illolin MDMA fiye da shekaru talatin. An ɗaure shi tare da gudanar da bincike mai zurfi a cikin maganin, wanda mafi yawan kwanan nan ya kasance gwajin gwaji na asibiti da yawa da kuma nazarin mataki na biyu na III.
Nazarin na biyu ya tabbatar da sakamakon binciken kashi na farko na III. Bisa ga MAPS, fiye da 86% na mahalarta da suka karbi maganin taimakon MDMA sun sami ci gaba "ma'anar asibiti" makonni 18 bayan fara gwajin. Fiye da 71% na mahalarta waɗanda suka karɓi maganin MDMA-taimako kuma sun daina cika ka'idojin bincike don PTSD a ƙarshen binciken, idan aka kwatanta da sama da 46% na mahalarta waɗanda suka karɓi placebo da far.
Psychedelics da hanyoyin kwantar da hankali suna ba da damar marasa lafiya su shiga cikin ingantaccen tunani da tunani don aiwatar da PTSD. "Ba ni da wata shakka cewa a halin yanzu muna shaida yadda aminci da alhakin amfani da masu tabin hankali ke haifar da zamanin juyin juya hali don ilimin hauka da ilimin halin mutum," in ji Mercer. Tana tsammanin FDA za ta amince da maganin a shekara mai zuwa.
Source: Militarytimes.com (En)
